Fig. 4From: Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panelPerceived impact of treatment on aspects of caregiver QoL. Key: QoL, quality of lifeBack to article page